Articles From: Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Ocwen Financial Corporation -- OCN to Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S)


NEW YORK, July 16, 2014 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court, District of New Jersey on behalf of all persons who purchased or otherwise acquired the securities of Regado Biosciences, Inc. ("Regado" or the "Company") (Nasdaq:RGDO) during the period between August 22, 2013 and July 9, 2014, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). The Complaint alleges that throughout the Class Period, Defendants made false and/or materially misleading statements about the Company's business, operations, prospects and performance.
Sign-up for Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Regado Biosciences, Inc. -- RGDO investment picks
NEW YORK, July 10, 2014 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court for the Central District of California on behalf of all persons who purchased or otherwise acquired the securities of STAAR Surgical Company ("STAAR" or the "Company") (Nasdaq:STAA) during the period between February 27, 2013 and June 30, 2014.
Sign-up for Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against STAAR Surgical Company investment picks
NEW YORK, July 18, 2014 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed in the United States District Court, District of Delaware on behalf of all persons who purchased or otherwise acquired the securities of The Bancorp, Inc. ("The Bancorp" or the "Company") (Nasdaq:TBBK) during the period between April 24, 2013 and June 10, 2014, inclusive (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). The Complaint alleges that throughout the Class Period, Defendants made materially false and misleading statements regarding (i) the Company had under-reserved for loan losses due to adverse loans; and (ii) the Company's operations and credit practices were in violation of the Bank Secrecy Act ("BSA"). As a result of the above, the Complaint alleges the Company's financial
Sign-up for Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against The Bancorp, Inc. -- TBBK investment picks
NEW YORK, July 25, 2014 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that they have filed a class action lawsuit on behalf of their client and others in the United States District Court for the Central District of California on behalf of all persons who purchased or otherwise acquired the securities of NetSol Technologies, Inc. ("NetSol" or the "Company") (Nasdaq:NTWK) during the period between March 10, 2011 and November 8, 2013, inclusive (the "Class Period") (the "Class Period"). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act"). The Complaint alleges that throughout the Class Period, Defendants issued materially false and/or misleading statements because: (a) NetSol's next generation product was not expected to be completed when promised by the Company; (b) serious interest in NetSol's next generation solution had not been
Sign-up for Gainey McKenna & Egleston Announces They Have Filed a Class Action Lawsuit Against NetSol Technologies, Inc. -- NTWK investment picks
2014/7/28
NEW YORK, July 28, 2014 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston has filed the first and only class action lawsuit and issues a corrected notice to clarify the class period.
Sign-up for Gainey McKenna & Egleston Filed the First and Only Securities Class Action Lawsuit Against NetSol Technologies, Inc. and Issues a Corrected Notice to Clarify Class Period -- NTWK investment picks
LAS VEGAS, Aug.
Sign-up for Galaxy Gaming Enters Czech Republic investment picks
LAS VEGAS, June 25, 2014 (GLOBE NEWSWIRE) -- Galaxy Gaming, Inc. (OTC:GLXZ) the world's largest independent producer of casino table games and enhanced systems, announced today the installation of its proprietary table games in France.
Sign-up for Galaxy Gaming Expands Its European Operations Into France investment picks
NEW ORLEANS, July 31, 2014 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C.
Sign-up for GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Galectin Therapeutics Inc. -- GALT investment picks
2014/8/11
Former United States Securities and Exchange Commission attorney Willie Briscoe , founder of The Briscoe Law Firm, PLLC , and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit has been filed against Galectin Therapeutics, Inc. (“Galectin” or “Company”) (NasdaqCM: GALT) and several officers and directors for acts taken during the period of January 6, 2014 to July 28, 2014 (the “Class Period”). Based upon the allegations in the class action, the firms are investigating additional legal claims against the officers and Board of Directors of Galectin.
Sign-up for Galectin Shareholder Alert: Former SEC Attorney Willie Briscoe and Powers Taylor Investigate Possible Breaches of Fiduciary Duty by Officers and Directors investment picks
Shareholder rights law firm Johnson & Weaver, LLP has commenced an investigation into whether certain officers and directors of Galectin Therapeutics Inc. (NASDAQ: GALT) violated state or federal laws.
Sign-up for GALECTIN SHAREHOLDERS NOTICE: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Galectin Therapeutics Inc. investment picks
NORCROSS, Ga., July 9, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced that it has been added to the Russell 3000® Index and Russell 2000® Index when Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 27, 2014.
Sign-up for Galectin Therapeutics Added to Russell 2000 Index investment picks
NORCROSS, Ga., July 22, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that the first patient has been dosed in cohort 1 of the Company's Phase 1B clinical trial evaluating GR-MD-02 in combination with ipilimumab (Yervoy®) in patients with metastatic melanoma.
Sign-up for Galectin Therapeutics Announces First Patient Dosed in Cohort 1 of Phase 1B Clinical Trial of GR-MD-02 in Combination with Ipilimumab in Metastatic Melanoma investment picks
NORCROSS, Ga., June 23, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that a preclinical study in a mouse model of NASH (non-alcoholic steatohepatitis, or fatty liver disease) demonstrated that oral administration of the Company's lead galectin-3 inhibitor, GR-MD-02, resulted in significant disease improvement.
Sign-up for Galectin Therapeutics Announces That Oral Treatment With Galectin-3 Inhibitor GR-MD-02 is Efficacious in Preclinical Model of Fatty Liver Disease With Fibrosis investment picks
NORCROSS, Ga., July 30, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced yesterday results of cohort 2 of its phase 1 clinical trial in patients with NASH with advanced fibrosis.
Sign-up for Galectin Therapeutics Issues Statement on GR-MD-02 Development Program investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Reports Second Quarter 2014 Financial Results investment picks
NORCROSS, Ga., Aug.
Sign-up for Galectin Therapeutics Responds to Class Action Lawsuit investment picks
NORCROSS, Ga., July 25, 2014 (GLOBE NEWSWIRE) -- Galectin Therapeutics (Nasdaq:GALT) , the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced the Company will hold a webcast on Tuesday, July 29, 2014 at 8:30 a.m. Eastern Daylight Time to discuss the findings from cohort 2 of a Phase 1 clinical trial evaluating its galectin inhibitor GR-MD-02 in fatty liver disease (NASH) with advanced fibrosis.
Sign-up for Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis investment picks
PORTLAND, Ore., June 17, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the completion of enrollment in the Company's Phase 2a clinical trial for GALE-301, or Folate Binding Protein (FBP) peptide immunotherapy.
Sign-up for Galena Biopharma Completes Enrollment in GALE-301 Phase 2a Clinical Trial in Ovarian and Endometrial Cancers investment picks
2014/7/22
Novel, rapidly dissolving oral PharmFilm® enables faster absorption, increased convenience and better compliance for patients.
Sign-up for Galena Biopharma Enters Into Definitive Agreement to License U.S. Rights for Zuplenz(R) (ondansetron) Oral Soluble Film investment picks
PORTLAND, Ore., July 1, 2014 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq:GALE) , a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major unmet medical needs to advance cancer care, today announced the notice of allowance of a U.S. Patent for NeuVax™ (nelipepimut-S) covering the use of NeuVax alone or in combination to prevent recurrence of any HER2/neu expressing tumor having a fluorescence in situ hybridization (FISH) rating of less than about 2.0. NeuVax is a peptide immunotherapy for the prevention of cancer recurrence and is Galena's lead development agent in multiple ongoing and planned clinical trials.
Sign-up for Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S) investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Gainey McKenna & Egleston Announces a Class Action Lawsuit Has Been Filed Against Ocwen Financial Corporation -- OCN to Galena Biopharma Receives Notice of Allowance of Broad U.S. Patent for NeuVax(TM) (nelipepimut-S)
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices